



IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicants: MANSTEIN *et al.*

Atty. Dkt. No.: 1974.0

Serial No.: 10/044,303

Examiner: Steadman, D.

Filing Date: January 11, 2002

GAU: 1652

Title: PROTEIN EXPRESSION AND STRUCTURE SOLUTION USING SPECIFIC FUSION VECTORS

Assistant Commissioner for Patents  
Washington, D.C. 20231

**SUBMISSION OF CERTIFIED COPY OF FOREIGN PRIORITY DOCUMENT**

Dear Sir:

The above-captioned patent application claims the benefit of the filing date of EP Patent Application No. 01100762.2. This claim for foreign priority was made at the time of filing.

In compliance with the requirements of 35 USC §119(b), a certified copy of the application for which a claim for foreign priority is made is enclosed herewith.

Respectfully submitted,

November 8, 2002

Candice J. Clement, Esq.  
Attorney for Applicants  
USPTO Registration Number 39,946  
HESLIN ROTHENBERG FARLEY & MESITI P.C.  
5 Columbia Circle  
Albany, New York 12203  
Telephone: (518) 452-5600  
Facsimile: (518) 452-5579

RECEIVED  
NOV 19 2002  
TECH CENTER 1608-2300

#9/jrw  
01-16-03





Europäisches  
Patentamt

European  
Patent Office

Office européen  
des brevets



Bescheinigung

Certificate

Attestation

RECEIVED  
NOV 19 2002  
TECH CENTER 1600/1200

Die angehefteten Unterla-  
gen stimmen mit der  
ursprünglich eingereichten  
Fassung der auf dem näch-  
sten Blatt bezeichneten  
europäischen Patentanmel-  
dung überein.

The attached documents  
are exact copies of the  
European patent application  
described on the following  
page, as originally filed.

Les documents fixés à  
cette attestation sont  
conformes à la version  
initialement déposée de  
la demande de brevet  
européen spécifiée à la  
page suivante.

Patentanmeldung Nr. Patent application No. Demande de brevet n°

01100762.2

Der Präsident des Europäischen Patentamts;  
Im Auftrag

For the President of the European Patent Office

Le Président de l'Office européen des brevets  
p.o.

R C van Dijk

DEN HAAG, DEN  
THE HAGUE,  
LA HAYE, LE

14/03/02





Europäisches  
Patentamt

European  
Patent Office

Office européen  
des brevets

**Blatt 2 der Bescheinigung**  
**Sheet 2 of the certificate**  
**Page 2 de l'attestation**

Anmeldung Nr.:  
Application no.: 01100762.2  
Demande n°:

Anmeldetag:  
Date of filing: 12/01/01  
Date de dépôt:

Anmelder:  
Applicant(s):  
Demandeur(s):  
Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V.  
80539 München  
GERMANY

Bezeichnung der Erfindung:  
Title of the invention:  
Titre de l'invention:  
Protein expression and structure resolution using specific fusion vectors

In Anspruch genommene Priorität(en) / Priority(ies) claimed / Priorité(s) revendiquée(s)

Staat:	Tag:	Aktenzeichen:
State:	Date:	File no.
Pays:	Date:	Numéro de dépôt:

Internationale Patentklassifikation:  
International Patent classification:  
Classification internationale des brevets:  
C07K1/22

Am Anmeldetag benannte Vertragsstaaten:  
Contracting states designated at date of filing: AT/BE/CH/CY/DE/DK/ES/FI/FR/GB/GR/IE/IT/LI/LU/MC/NL/PT/SE/TR  
Etats contractants désignés lors du dépôt:

Bemerkungen:  
Remarks:  
Remarques:

1. The first part of the report is a general introduction to the subject.

2. The second part is a detailed description of the method used.

3. The third part is a discussion of the results obtained.

4. The fourth part is a conclusion and summary of the work.

5. The fifth part is a list of references.

6. The sixth part is a list of figures and tables.

7. The seventh part is a list of appendices.

**SAMSON & PARTNER**

PATENTANWÄLTE · EUROPEAN PATENT ATTORNEYS · EUROPEAN TRADE MARK ATTORNEYS

UNSER ZEICHEN/OUR REF  
M1984-003-EPP00Sk  
vS/27/kk/rgDATUM/DATE  
12. Januar 2001

Anmelderin:  
Max-Planck-Gesellschaft  
zur Förderung der Wissenschaften e.V.  
Hofgartenstr. 8  
80539 München

EPO - Munich  
24  
12. Jan. 2001

5      **Protein Expression and Structure Solution using specific  
Fusion Vectors**

10      The present invention relates to a recombinant protein  
being composed of three components (1), (2) and (3), a  
DNA sequence encoding such a recombinant protein, a  
vector expressing such a recombinant protein, a host cell  
transformed with a vector, a method for producing a  
recombinant protein, and methods for purification,  
crystallization and structure elucidation of the  
recombinant protein.

15      The first step, and perhaps the single most important  
step, in the crystallization of a macromolecule, e.g. a  
protein, is its purification. Any impurities of the  
protein solution to be used for crystallization may  
impair crystal quality or, even worse, preclude the  
20      formation of crystals at all.

25      Procedures for accomplishing the highest degree of  
purification possible have been under development for  
more than 200 years, and recent times have seen an  
explosion in the invention of new methods and refinement  
of old. There is a variety of methods that exemplify how

problems of protein purification for protein analysis or protein crystallization have been approached.

One such method is fractionation with salts and other precipitants. Hereby, proteins are precipitated from a complex mixture (e.g. a physiological fluid) by addition of various concentrations of different salts. Because individual proteins precipitate at different salt concentrations, this "salting out" phenomenon provided a method for selectively precipitating, and thereby purifying, unique proteins from a mixture (Morris and Morris, 1964, Separation methods in biochemistry, Pitman, London, GB). A minor disadvantage of salt fractionation is that protein preparations, be they supernatants or precipitates, are left with high residuals of salt. This may seriously interfere with the evaluation of activity and purity and with subsequent purification procedures. The most common of these methods is dialysis in celluloid or collodian tubes.

Apart from varying the concentration of a salt, proteins may be selectively precipitated and fractionated by the addition of a variety of organic solvents (Cohn et al., 1947, Crystallization of serum albumin from ethanol/water mixtures, J. Am. Chem. Soc. 69, 1753). This is generally carried out at subzero temperatures ranging to  $-30^{\circ}\text{C}$  to enhance the precipitation effect and to minimize the denaturation of the protein. In addition to salt and organic solvents, other materials have been used to precipitate and fractionate a mixture of proteins. Some of these materials are, for example, protamine (a mixture of small basic proteins) and polyeneimine (a basic organic polymer), which apparently cross-links some protein via electrostatic bridges. Moreover, metal ions or organic polymers, such as polyethylene glycol (PEG), were extensively used for purification purposes. PEG seems to act as a hybrid between an alcohol and a salt



and their precise properties may vary as a function of mean polymer length.

5 Still another method of protein purification is the selection of proteins with heat or pH. pH is effective because most proteins exhibit pH-dependent solubility minima and precipitate or even crystallize from solution at particular values, whereas the property of protein heat stability may sometimes provide a valuable  
10 purification step.

Other protein purification methods based on physical techniques are also well-known to a person skilled in the art. E.g. centrifugation has to be mentioned, whereby a  
15 solution containing multiple components varying in weight, size, and density is deployed in a tube and rotated at high angular velocity. An almost preparative centrifugation is conducted on some gradient with various density from the top to the bottom of the centrifuge  
20 tube. Two common techniques utilized in connection with density gradient separation are sedimentation velocity and sedimentation equilibrium or isopycnic centrifugation. Furthermore, electrophoretic separation methods (Svensson, 1947, Preparative electrophoresis and  
25 ionophoresis, Adv. Protein Chem. 4:251) are routinely used and are based on the application of an electrical field across and insoluble, porous support medium permeated by a buffer solution. Dependent on the net charge of the proteins to be separated they will  
30 experience and electromotive force and migrate toward one electrode (cathode or anode). For the separation of proteins, polyacrylamide gels as support medium have shown to have almost ideal properties.

35 Finally, chromatographic methods are especially well suited to separate proteins and to purify the target protein for later crystallization steps. Classic ion exchange chromatography is simply conducted by packing a

vertical hollow glass column with an insoluble resin or colloidal matrix that exhibits an array of positively charged (anion exchange chromatography) or negatively charged chemical groups (cation exchange chromatography).

5 Ion exchange chromatography is based on the fact that a positively charged protein will be retarded or bound to electrostatic interactions with a matrix carrying negatively charged groups or vice-versa for negatively charged proteins. Dependent on their respective net  
10 charge the proteins to be separated will appear in the eluent sequentially with time (or volume). Molecules tightly bound to the matrix may be eluted from the column by competition with other charged ions. In contrast to ion exchange chromatography, molecular sieve  
15 chromatography (also called gel permeation chromatography) separates molecules on the basis of molecular weight and shape. Hereby, macromolecules, like proteins, are induced to flow by gravity or pressure through a column containing a matrix of microscopic beads  
20 perforated with a vast network of channels. Thereby, the high molecular sieving effect will influence the speed in passing from the top to the bottom of the column leading to the inverse effect that larger molecules will appear first in the column eluent. Finally, absorption  
25 chromatography, HPLC (high performance liquid chromatography), and affinity chromatography are also well established as biochemical purification methods.

30 All of the above-mentioned methods exhibit certain advantages and disadvantages. Consequently, the person skilled in the art will choose the purification method which appears to be most appropriate for a given system.

35 Since a number of years purification methods take advantage of recombinant proteins (Kane and Hartley, 1988, Development of expression systems for production of high levels of protein, Trends Biotechnol. 6: 95). Recombinant proteins are produced by recombinant DNA

techniques in bacteria, yeast or other organisms such as virus infected mammalian or insect cells. The advantage of recombinant proteins is based on genetically designed elements, that aid the biochemist in applying one of the  
5      aforementioned physical or biochemical purification methods. For example, a series of histidine residues, a so-called "his-tag", may be appended to the carboxyl terminus of a recombinant protein. Such a histidin-  
10      appendix makes it easier to isolate the expressed protein on a copper or nickel containing chromatographic resin, the latter being available commercially in prepacked columns.

A second procedure in wide use for the purification of  
15      recombinant proteins is the fusion of an expressed protein with the enzyme glutathione sulfur transferase (GST). This enzyme has a very high affinity for the small peptide glutathione. Following expression of the protein, an extract of the cells is passed over a small  
20      chromatography column containing a matrix conjugated with glutathione. The chimeric protein is then reversibly bound on the column through the GST, contaminants are washed from the column, and finally the recombinant protein is eluted with free glutathione and collected.  
25      The GST may then be cleaved from the chimera by a specific protease to produce the free recombinant protein. Again, the chromatographic matrix may be obtained commercially in prepacked columns.

30      Furthermore, e.g. pMAL<sup>TM</sup> (by New England Biolabs Inc.) is used as protein fusion and purification system as prior art. This system comprises the insertion of the cloned gene into a pMAL vector downstream from the maltE gene, which encodes maltose binding protein (MBP). The fusion  
35      protein (target protein and MBP) is expressed in large quantities and purified by affinity chromatography for MBP using amylose resin. Finally, MBP is cleaved from the target protein by a specific protease.

These techniques utilizing recombinant proteins allow to obtain extraordinarily pure fractions of the target protein. However, advantageous conditions for purification, crystallization and structural analysis have to be tested using the MBP/target protein or GST/target protein fusion systems for each single recombinant and/or target protein. Particularly, (i) there are still complex chromatographic (in vitro) purification steps required for obtaining pure fractions of the target protein and (ii) further steps of analysis, like crystallization or structure determination, are complicated by the unknown properties of the target protein, like e.g. the crystallization conditions of a specific target protein purified as MBP or GST fusion protein.

The object of the present invention is to overcome the above-mentioned disadvantages of the prior art, particularly to provide a system which allows to reduce considerably the time effort for purification and subsequent crystallization as well as structure determination of any protein to be analysed.

This object is achieved by a recombinant protein according to claim 1, a DNA sequence encoding such a protein according to claim 8, a vector according to claim 10, a transformed host cell according to claim 12, a method for producing a recombinant protein according to claim 14, and methods for purification, crystallization and structure elucidation according to claims 15, 21 and 23.

Therefore, it is an object of the present invention, in one aspect, to provide recombinant proteins which contain as component (1) an amino acid sequence of a member of the myosin or kinesin protein superfamilies or an amino acid sequence of an analog, fragment or derivative of a

member of the myosin or kinesin protein superfamilies, as component (2) any amino acid sequence of at least 20 amino acids in length (target protein sequence), and as component (3) a linker region of at least 2 amino acids  
5 between components (1) and (2) (claim 1). However, the subject-matter of the present invention works with any protein or fragment, derivative or analog thereof as component (1), which binds to a any molecule or structure of the cytoskeleton or a cell membrane in a ligand  
10 dependent manner. Particularly preferred as component (1) are molecules, which exhibit a flexible region, particularly at the C-terminal region of component (1), in order to sample for multiple conformations.

As mentioned above, the present invention further  
15 concerns analogs, fragments and derivatives of the recombinant protein of the invention. The preparation of such analogs, fragments and derivatives is by a standard procedure (Sambrook et al. (1989), Molecular Cloning: A Laboratory Manual, Cold Spring Harbor, New York) in which  
20 in the DNA sequences encoding the inventive recombinant protein, one or more codons may be deleted, added or substituted by another, to yield analogs having at least one amino acid residue change with respect to the native recombinant protein, particularly with respect to the  
25 native amino acid sequence of component (1) or of component (2) of the recombinant protein of the invention.

Analogues that substantially correspond to the native sequence of one or more components of the inventive  
30 recombinant protein are those polypeptides, in which one or more amino acids of the native protein's amino acid sequence has/have been replaced by another amino acid, deleted and/or inserted. In a preferred embodiment of the present invention, the resulting components ((1) or (2))  
35 being incorporated into the recombinant protein of the invention exhibit substantially the same or even higher

biological activity as the corresponding native protein to which it corresponds or exhibit at least structurally similar properties as the native protein to which the component corresponds. In order to substantially correspond to the native sequence of component (1) or (2) of the recombinant protein of the invention, the changes in the sequence of the components are generally and preferably relatively minor, such as isoforms. Although the number of changes may be more than 10, preferably there are no more than 10 changes, more preferable no more than 5 and most preferably no more than 3 changes in component (1) or (2) as compared to the respective native sequence. While any technique may be used to find potentially biologically active sequences of a component of the inventive recombinant protein, which substantially correspond to the respective native proteins, one such technique is the use of conventional mutagenesis techniques on the DNA encoding the protein, resulting in a few modifications. The sequences used for component (1) or (2) in the recombinant protein of the invention which are expressed by such clones, may then be screened for their ability e.g. to bind to their native binding partners, mediate activity etc. , in other words fulfil their biological role.

Conservative "changes" are those changes which would not be expected to change the activity of the protein and are usually the first to be screened as these would not be expected to substantially change size, charge or structure of the polypeptide sequence used as component in the recombinant protein of the invention and thus would not be expected to change the biological properties of the corresponding native sequence. For example, conservative substitutions are assumed, if (a) small aliphatic, non-polar or slightly polar residues are substituted by other residues belonging to the same group, (b) polar negatively charged residues and their amides are exchanged for other residues belonging to the

same group, (c) polar positively charged residues are exchanged for polar positively residues, (d) large aliphatic non-polar residues are exchanged for large aliphatic non-polar residues, and (e) finally, aromatic residues are substituted by other aromatic residues. In most cases, analogs being used as component (1) or (2) of the recombinant protein of the invention are defined (according to the present invention) as sequences with substitutions which do not produce radical changes in the characteristics of the corresponding native protein or polypeptide molecule. Characteristics may be the specific secondary structure of a sequence, e.g.  $\alpha$ -helix or  $\beta$ -sheet, as well as its specific biological activity.

It is noted that apart from sequences being used as component (1) or (2) for a recombinant protein according to the present invention, which are based on conservative substitutions as discussed above, analogs with more random changes, which lead to a radical or more radical change in biological activity or structure of the analog as compared to the native sequence are also within the scope of the present invention.

At the genetic level, these analogs are generally prepared by site-directed mutagenesis of nucleotides in the DNA encoding the inventive recombinant protein or the component of the recombinant protein, respectively, thereby producing DNA encoding the analog and thereafter synthesizing the DNA and expressing the polypeptide in recombinant cell culture. Insofar, it is referred to Ausübel et al., Current Protocols in Molecular Biology, Green Publications and Wiley Intersigns, New York, New York, 1987 - 1995; Sambrook et al., Molecular Cloning: Laboratory Manual, Cold Spring Harbor Laboratory, New York, 1989, the disclosure of which is incorporated herein by reference. Furthermore, site-specific mutagenesis allows the production of analogs through the use of specific oligonucleotide sequences that encode the

10

DNA sequence of the desired mutation. The technique of site-directed mutagenesis is exemplified by publications such as Adelman et al., DNA 2: 183 (1983)), the disclosure of which is incorporated herein by reference.

5 Typical vectors useful in site-directed mutagenesis include vectors such as M13-phage, for example as disclosed by Messing et al., (3<sup>rd</sup> Cleveland Symposium on Macromolecules and recombinant DNA, editor A. Walton, Elsevier, Amsterdam (1981)), the disclosure of which is

10 incorporated herein by reference.

As far as derivatives of the native sequence of components of the recombinant protein of the present invention are concerned, derivatives may be prepared by standard modifications of the side groups of one or more

15 amino acid residues of the recombinant protein of the invention, its analogs or fragments or by conjugation of the native sequence used as component (1) or (2) of the inventive recombinant protein, its analogs or fragments, to another molecule, e.g. an antibody, enzyme, receptor,

20 etc. Accordingly, "derivatives" as used herein cover derivatives which may be prepared from the functional groups which occur as side chains on the residues or from the N- or C- terminal groups by means known in the art. Derivatives may have chemical moieties such as

25 carbohydrates or phosphate residues. For example, derivatives may include aliphatic esters of the carboxyl groups, amides of the carboxyl group by reaction with ammonia or with primary or secondary amines, N-acyl derivatives or free amino groups of the amino acid

30 residues formed with acyl moieties or O-acyl derivatives of free hydroxyl groups (for example of seryl or threonyl residues) formed with acyl moieties. The term derivative includes - generally spoken - all polypeptide sequences for one component (1 and/or 2) of the recombinant protein

35 sequence which are larger in sequence than the corresponding native sequence. The addition of at least one, typically more than 10 amino acids may take place



intrasequentially or at the N- or C-terminus of the sequence of component (1) and/or (2) of an inventive recombinant protein. In a preferred embodiment of the present invention, additional amino acids are appended to the N-terminus of component (1) or the C-terminus of component (2) coinciding with the N-terminus and the C-terminus of the inventive recombinant protein. In another preferred embodiment, additional amino acid sequences are inserted intrasequentially, preferably in such a way that the secondary and/or tertiary structure is not destroyed. Typically these insertions are placed at the surface of the protein, e.g. in  $\beta$ -bends. Preferably, one or more S-containing residues (particularly Cys) are inserted or other residues with a potential for binding heavy metal atoms (e.g. Hg-ions). The introduction of additional heavy metal binding residues at sites on the surface of the recombinant protein of the invention may be accompanied by substitution and/or deletion of native heavy metal binding residues in order create novel heavy metal atom binding sites. Such a procedure is particularly suitable for gaining additional phasing information for structure determination of large protein complexes by X-ray crystallography.

In a non-limiting manner, "tag"-sequences may be contained in the recombinant protein and, particularly, may be added to the N- or C-terminus of the recombinant protein of the invention (claim 7). These "tag"-sequences typically have antigenic character for commercially available antibodies, e.g. an N-terminal "Flag-tag" having the sequence DYKDDDDK (one-letter-code). Other suitable "tag"-sequences are, for example, N- or C-terminal polyhistidine tags.

Furthermore, component (1) and/or (2) as parts of the recombinant protein of the invention may be fusion proteins. Particularly preferred are sequences fused to the N-terminus of the native sequence of component (1) or

to the N-terminus of an analog, derivative or fragment thereof. For example, component (1) of the recombinant protein may be fused N-terminally to a marker protein, e.g. an enzyme marker or a fluorescence marker, such as GFP (green fluorescence protein), or any sequence being  
5 suitable as epitope for an antibody or even to an antibody or an antibody fragment itself.

Finally, "fragments" of the native sequence of any protein being used as component (1) or (2) of the  
10 recombinant protein according to the present invention may be used, e.g. fragments of proteins of the myosin or kinesin protein superfamilies, particularly fragments being deleted C-terminally, the deletion comprising at least ten, and more preferably at least 50 amino acids.  
15 However, the fragment of the native sequence may also contain deletions at the N- and/or C- terminus and/or intrasequentially in component (1) and/or component (2) of a recombinant protein of the invention. In a preferred embodiment, component (1) consists of a fragment  
20 comprising the catalytic domain of a member of the myosin or kinesin protein superfamilies of any eukaryotic organism. In other words, component (1) corresponds preferably to a fragment containing the myosin or kinesin motor domain. Within the scope of the present invention  
25 are therefore recombinant proteins characterized in that they contain as component (1) an amino acid sequence for the motor domain of a kinesin or myosin family member or an analog, fragment or derivative thereof (claim 3).

In a preferred embodiment of the present invention, the  
30 recombinant protein according to the present invention contains as component (1) an amino acid sequence of a member of the myosin I, II, III, IV, V, VIII, VI, X, or XI or a member of kinesin I or II families or an amino acid sequence of an analog, fragment or derivative of a  
35 member of the aforementioned myosin and kinesin families (claim 2). Preferably, component (1) contains a member of

the myosin II family of any eukaryotic organism or an analog, fragment or derivative thereof. Still further preferred, component (1) contains myosin II of *Dictyostelium* or an analog, fragment or derivative thereof. Further preferred embodiments of the present invention for component (1) are proteins containing the motor domains of smooth muscle myosin II (e.g. chicken gizzard myosin), vertebrate or amoeboid forms of myosin I (bovine brushborder myosin), *Dictyostelium* myoID, vertebrate myosin V, myosin VI, *Toxoplasma gondii* (e.g. TgMyoA) and *Plasmodium* sp. myosin XIV, vertebrate kinesin (human kinesin I), amoeboid or fungal kinesins (e.g. *Dictyostelium* kinesin 7).

Preferably, a recombinant protein according to the present invention contains as linker component (3) a stretch of at least 3 amino acids, more preferably 5 and still further preferably 10 amino acids. Particularly preferred is a linker sequence, which contains a protease cleavage site. A recognition sequence for any protease may be used, for example, the cleavage site may contain the recognition sequence for factor Xa, thrombin or for the protease TEV (recognition sequence: ENLYFQG) or the Soldati protease. However, it is within the scope of this invention that component (1) and (2) are directly fused together without insertion of a linker sequence.

If linker component (3) consists of three amino acids, it is preferred to chose a sequence with at least one Gly residue, particularly in the second position of the linker stretch (claim 4). Still further preferred is a linker with the following sequence: N-Leu-Gly-Arg-C.

Recombinant protein according to any of the preceding claims characterized in that it contains as component (2) (target protein) the sequence of an esterase, hydrolase, phosphatase, kinase, protease, channel, structural protein (e.g. coronin, spectrin), receptor, particularly

a neuronal or immunologically relevant receptor (e.g. superfamily of TNF receptors), transcription factor, DNA/RNA-binding protein, lipoprotein, glycoprotein or an analog, derivative or fragment thereof (claim 5).

5 Particularly, a recombinant protein according to the present invention has as component (1) an amino acid sequence as exhibited in figure 6 or an analog, derivative and/or fragment thereof. It is preferred to  
10 combine the sequence of figure 6 with a linker sequence (3) containing a protease recognition site as exemplified above or amino acid sequence Leu-Gly-Arg (claim 6). Still further preferred is a recombinant protein having a sequence as shown in fig. 7.

15 A second aspect of the present invention relates to a DNA sequence which contains a sequence which codes for an amino acid sequence (for a recombinant protein) according to the present invention (claim 8). In particular, the present invention provides a DNA sequence selected from  
20 the group consisting of: (a) a cDNA sequence derived from the coding region of a recombinant protein according to the present invention; (b) DNA sequences capable of hybridization to a sequence of (a) under moderately stringent conditions; and (c) DNA sequences which are  
25 degenerate as a result of the genetic code to the DNA sequences defined in (a) and (b). Another specific embodiment of the above DNA sequence of the invention is a DNA sequence comprising at least part of a sequence encoding for a recombinant protein as depicted in fig. 8, particularly the segment of fig. 8 which codes for the  
30 myosin motor domain. Nucleic acid stretches encoding for a recombinant protein of the present invention may be detected, obtained and/or modified, in vitro, in-situ and/or in vivo, by the use of known DNA or RNA amplification techniques, such as PCR and chemical  
35 oligonucleotide synthesis. PCR allows for the amplification (increase in number) of a specific DNA

sequence by repeated DNA polymerase reactions. This reaction may be used as a replacement for cloning. All that is required is a knowledge of the nucleic acid sequence. In order to carry out PCR, primers are designed which are complementary to the sequence of interest. The primers are then generated by automated DNA synthesis. Because primers may be defined to hybridize to any part of the gene, conditions may be created such that mismatches in the complementary base pairing may be tolerated. Amplification of these mismatch regions may lead to the synthesis of a mutagenized product resulting in the generation of a polypeptide with new properties (site-directed mutagenesis). Also, by coupling complementary DNA (cDNA) synthesis, using reverse transcriptase, with PCR, RNA may be used as the starting material for the synthesis of a recombinant protein of the invention. Furthermore, PCR primers may be designed to incorporate new restriction sites or other features such as termination codons at the end of the segment to be amplified. This placement of restriction sites at the 5' and 3' ends of the amplified nucleic sequence allows for gene sequence including a recombinant protein of the invention or a fragment thereof to be custom designed for ligation with other sequences and/or cloning sites in vectors.

PCR and other methods of amplification of RNA and/or DNA are well known in the art and may be used according to the present invention without undue experimentation. Known methods of DNA and RNA amplification include polymerase chain reaction and related amplification processes (Innes et al., PCR Protocols: A Guide to Method and Amplification) and RNA mediated amplification which uses antisense RNA to the target sequence as a template for double stranded DNA synthesis (US Patent 5,130,238). In an analogous fashion, a recombinant protein of the invention being composed of components 1, (2) and 3 as defined above may be prepared, whereby components 1, (2)

and 3 are ligated on a genetic level forming a DNA sequence of the invention, which is used to express a recombinant protein of the invention in a suitable host system.

5 Also provided by the present invention are vectors encoding the above recombinant protein, and analogs, fragments or derivatives of the invention, which contain the above DNA sequence of the invention these vectors being capable of being expressed in suitable eukaryotic  
10 or prokaryotic host cells (claims 9, 10). Particularly preferred are vectors of the invention, which are capable of being expressed in cells of the species *Dictyostelium* (claim 11).

15 In this embodiment (expression vector) of the present invention the DNA sequence is operably linked to a promoter, preferably linked upstream. The promoter will preferably be an eukaryotic promoter, particularly a constitutive promoter. The transcription of a DNA  
20 sequence according to the invention in cells of higher eukaryotes may be derived from viral genomes. Examples would be polyoma viruses, retroviruses, adenoviruses, cytomegaloviruses, SV40 and the like. With mammalian cells a possibility would be the  $\beta$ -actin promoter. In the current invention, the actin15 promoter is particularly  
25 preferred for expression in *Dictyostelium*. If appropriate, other regulating elements of transcription and/or translation will be provided. Particularly preferred are cis-acting elements, like enhancer sequences, which usually include 10 to 300 base pairs and  
30 act upon the promoter to raise the transcription rate. They may be arranged in the 3' or 5' position of the DNA sequence according to the invention, but also in the coding sequence itself or in an intron sequence which is cut out by splice procedures. Further regulating elements  
35 may serve to regulate transcription termination, so that the expression of mRNA is involved.

If necessary, the expression vector with the DNA of the invention are developed as shuttle vectors, that is, they are able to replicate in a host system and can then be transfected into another host system for purposes of expression. For instance, a vector can first be cloned in E.coli and then be inoculated into Dictyostelium, yeast or any mammalian cell for expression.

Typically, such expression and cloning vectors include at least one selection gene exercising a marker function. This is a gene allowing host cells to survive or grow after being transformed by the vector. Typical selection genes code for proteins which permit resistance toward antibiotics or other toxins. This, for instance, includes puromycin, ampicillin or neomycin.

Host cells, particularly eukaryotic host cells, transformed with an expression vector according to the invention are another subject of the present invention (claim 12). Appropriate host cells for cloning or expressing the DNA sequences are prokaryotic cells, yeast or higher eukaryotic cells. In a preferred embodiment, cells for expressing DNA sequences according to the invention are selected from multicellular organisms. This also takes place before the background of the function of component (1) of the recombinant protein of the invention to elements of the cytoskeleton (like actin or microtubules or even components of the cell membrane or membrane of any intracellular organelle, like mitochondria). In principle every eukaryotic cell can be used as host cell, even though cells of mammals, like monkeys, mice, rats, hamster or humans, are preferred. Particularly preferred are cells from the species Dictyostelium (claim 13).

The present invention relates in a further aspect to a method for producing a recombinant protein according to the invention, whereby the method comprises the following

steps: (a) preparing a vector according to the invention,  
(b) transforming eukaryotic host cells with a vector  
obtainable from step (a), and (c) growing transformed  
host cells of the invention and obtainable from step (b)  
5 under conditions suitable for the expression of said  
recombinant protein (claim 14). The expression method of  
the invention allows for overexpression of any target  
protein or polypeptide of at least 20 amino acid length  
(component (2)) as segment of the recombinant protein of  
10 the invention. Accordingly, huge amounts of target  
protein as part of a recombinant protein of the invention  
are produced by the method of the invention. It is  
preferred within the scope of the present invention to  
concentrate the overexpressed recombinant protein in the  
15 cell. This is achieved by constructing recombinant  
proteins of the invention, which do not carry any leader  
sequences for secretion out of the transformed host cell.

Another aspect of the present invention is a method for  
purifying a recombinant protein according to the  
20 invention or any other recombinant protein, which  
contains an amino acid sequence binding to cytoskeleton  
(actin or microtubules or proteins being bound to actin  
in the cell) or membrane (e.g. inner cell membrane or  
outer or inner membrane of a cell organelle) structures  
25 and another amino acid sequence (target sequence to be  
analysed), whereby the method comprises (a) preparing a  
vector according to the invention or a vector encoding  
for any recombinant protein (as disclosed above), (b)  
transforming eukaryotic host cells with a vector  
30 obtainable from step (a), (c) growing transformed host  
cells according to the invention and/or obtainable from  
step (b) under conditions suitable for the overexpression  
of said recombinant protein, (d) purifying overexpressed  
recombinant protein by binding to endogenous elements or  
35 structures of the cytoskeleton or membrane, like  
actin/microtubules, of the eukaryotic host cell, and (e)



releasing bound recombinant protein from these structures or elements, preferably actin or microtubules (claim 15).

In a preferred embodiment of said method for purifying of the invention provides in step (e), the releasing step, a  
5 separation from the structures or elements of the cell by adding a substrate, be it a natural or non-natural substrate, of component (1) of the recombinant protein (claim 16). Whereas in general the natural substrate will be used, it may be preferable in certain cases to use a  
10 non-natural substrate of component (1), like GTP or (nucleotide) analogues (where ATP is the natural substrate), for releasing purposes. In general, any substrate with the potential to release the bound recombinant protein, particularly by binding to the  
15 component (1) of the recombinant protein from the cell structure or element is suitable to be used for step (e). It will be appreciated that a method of the invention using a member of the kinesin or myosin superfamily or a derivative, fragment or analog thereof as component (1)  
20 is particularly preferred, if it is characterized in the addition of ATP, which is the natural substrate for these proteins with motility function (claim 17).

In a still further preferred embodiment, the purification method of the invention comprises an additional step (f).  
25 Step (f) may typically provide at least one additional in vitro purification step, whereby all common purification procedures available may be provided, for instance all procedures described by A. Mc Pherson (Crystallization of Biological Macromolecules, Cold Spring Harbor Laboratory  
30 Press, NY, 1999), which is incorporated herein by reference. In a non-limiting manner, the following methods, particularly biochemical and/or physical methods, may be used or combined: salt fractionation, desalting, fractionation with organic solvents or with  
35 other precipitants; selection with heat/pH, centrifugation, chromatographic methods, e.g. ion exchange

chromatography, molecular sieve chromatography, adsorption chromatography, affinity chromatography or HPLC, ultrafiltration, isoelectric focussing and/or electrophoresis by biochemical, particularly chromatographic, and/or physical methods (claim 18). Affinity chromatography is particularly preferred, whereby metals (e.g. Ni) and/or antibodies are typically bound to a resin as ligands (claim 19). The affinity chromatography may typically be carried out in batch mode or by a column packed with an insoluble support matrix.

A further aspect of the present invention is a recombinant protein, particularly in isolated and/or purified form, obtainable from a method for producing of the recombinant protein of the invention as described herein (claim 20).

A still further aspect of the present invention is a method for crystallizing a recombinant protein according to the invention characterized in that it comprises (a) a purification step according to a method of the invention and (b) a crystallization step (claim 21). Hereby, the purified recombinant protein obtained in step (a) is crystallized by any method known by the skilled person. The crystallizing step will be carried under conditions suitable for crystal growth. The conditions may be optimized by varying certain parameters, such as stock solution, concentration of the recombinant protein, temperature, pH, ionic strength, precipitating agent (e.g. ammonium sulfate or PEG), addition of small amounts of organic solvents etc. However, the conditions used for crystallization of component (1) alone are preferred, which means that the conditions suitable for a member of the myosin or kinesin superfamily or a fragment, analog or derivative thereof may also work to identify crystals of the recombinant protein of the invention. In order to accelerate the crystallization process, it is particularly preferred to apply a recombinant protein of

the invention containing as component (1) an amino acid sequence with a flexible region, particularly a flexible at C-terminal end of component (1). Thereby, a high degree of flexibility of the components is achieved  
5 resulting in numerous conformations which can be occupied or sampled by the components in the course of the crystallization process.

It is preferred to employ vapor diffusion techniques either by the hanging or the sitting drop method to  
10 obtain crystals. Furthermore, crystallization may be achieved by induction of nucleation. Macro- or microseeding methods are mentioned as described by A. Mc Pherson (Crystallization of Biological Macromolecules, Cold Spring Harbor Laboratory Press, NY, 1999), which is  
15 - by its whole contents - incorporated as disclosure of the present application by reference.

Another aspect of the present invention is a protein crystal characterized in that the crystal is built by a network of recombinant proteins according to the  
20 invention (claim 22). This network forms the crystal lattice. Within the scope of the present invention are crystals of any space group in which identical proteins can be arranged. A crystal of the invention may contain one, two, three or more recombinant proteins per  
25 asymmetric unit. At least one heavy atom may be located at (a) certain position/s in the recombinant protein being arranged symmetrically in the crystal of the invention. Crystals may contain ligands non-covalently bound to the crystallized recombinant protein as well,  
30 e.g. ATP, inhibitors, alkali ions or physiological ligands, such as hormones, carbohydrates, protein fragments etc.

Finally, an aspect of the present invention is a method for elucidating the atomic structure of a protein crystal  
35 of the invention, whereby, after a crystallization step

(a) according to the invention, X-ray diffraction data are collected on a beamline or any kind of device suitable for measuring locations of X-ray reflections (diffractometer, (b)). In final step (c), the atomic structure or rather the electron density map (into which the polypeptide chain and, eventually, other ligands and water molecules are modeled) of a recombinant protein is calculated by Fourier transformation of the data set obtained in step (b) using phasing information obtained by anomalous scattering, the heavy atom method or molecular replacement techniques (claim 23), as e.g. described by Stout & Jensen (X-ray Structure Determination, Wiley, NY, 1989), which is incorporated herein by reference. For the present invention molecular replacement methods are particularly useful. The phasing information may be obtained from component (1) as starting model, which is typically a structurally well determined polypeptide. Therefore, component (1) is a "helper" sequence providing the starting information to solve the structure of the recombinant protein or the structure of component (2), respectively, which is the target protein to be structurally analysed. Further rounds of structure refinement by methods known by the skilled person or described by Stout & Jensen may serve to improve the structure model. Additionally, heavy atoms may be bound to known sites of component (1) of the recombinant protein of the invention. Thereby, additional phasing information may be obtained for structure elucidation of target component (2) (which is under analysis) of the recombinant protein of the invention.

The use of a recombinant protein of the invention for purification and crystallization purposes has unprecedented advantages over the methods known in the art. The recombinant protein via its component (1) binds to insoluble components of the cell, like the cytoskeleton, membrane components or the like. Following cell lysis, the recombinant fusion protein (or rather its

component (2), which is wanted to be purified, analysed or subjected to X-ray analysis) can be enriched by ligand depletion and precipitation with the insoluble interaction partners of the cell. This allows for a purification step already carried out in the cell without any additional. Therefore, it is not the lysate as a whole which contains the overexpressed protein but the pre-purified precipitate itself. The specific solubilization of the fusion protein is achieved by addition of the ligand to the insoluble fraction. For crystallization, the conditions (parameters) are preferably chosen such that they coincide with the conditions for structurally well characterized component (1). These conditions or subtle variations of these conditions are expected to work for the recombinant protein as well. Hence, the method of the present invention for crystallizing allows to find crystallization conditions without extensive search for suitable parameters required by the art.

However, it is within the scope of the present invention that a recombinant protein of the invention or any other recombinant protein which is purified according to a method of the present invention may be structurally analysed by any other method known by the skilled person. Particularly, such recombinant proteins may be subjected to NMR analysis (two-dimensional or multidimensional) as described by Roberts (1993, NMR of Macromolecules: A practical approach, Oxford-New York), which is incorporated herein by reference. Furthermore, the system of the present invention may be used for drug design (ligand to component (2) of the recombinant protein used) as described by Craik (1996, NMR in drug design, CRC Press, Boca Raton), which is incorporated by reference. Other methods of structure elucidation are, for instance, mass spectrometry as described by Siuzdak (1996, Mass Spectrometry for Biotechnology, Academic Press, San Diego), incorporated herein by reference.

Another object of the present invention is the following subject-matter, namely a method for isolating and identifying proteins which are capable of binding to the target sequence used as component (2) in the recombinant protein (particularly of the invention). Therefore, a yeast-two-hybrid system may be used, by which a sequence encoding the recombinant protein is carried by one hybrid vector and sequence carried by the second hybrid vector, the vectors being used to transform yeast host cells and the positive transformed cells being isolated, followed by extraction of the said second hybrid vector to obtain a sequence encoding a protein which binds to said recombinant protein directly or indirectly via other proteins.

Furthermore, according to the present invention, an approach/method suitable for the identification of binding partners to the recombinant protein of the invention may comprise the following steps: (a) a library of cDNA is typically fused to the C-terminus of component (1), particularly of a myosin motor domain (MMD), (typically resulting in a recombinant protein of the invention), eventually via a linker sequence; (b) this recombinant protein is expressed in *Dictyostelium* or another eukaryotic system; (c) clonal transformants are probed with the bait-protein of choice fused to any marker protein, e.g.  $\beta$ -galactosidase; and (d) after washing identification and determination of interacting recombinant protein by measuring the activity of bait-marker fusion protein, e.g. by addition of  $\beta$ -gal. In a preferred embodiment, the myosin motor domain may be his- or epitope-tagged at the N-terminus. Typically all steps of the method of the invention are carried out in microtiter well plates.

Preferably, the recombinant protein shown to have bound to the bait-protein of choice may be purified by the methods of the invention and can then be subjected to further biochemical or structural characterization, e.g. crystallization as described above, with or without cleavage by a protease, if a recognition in a linker region has been provided, in order to release component (2), the target protein. The method of the invention is suitable for the identification of unknown binding partners and may also be used to demonstrate the interaction between two known polypeptides.

The method of isolating yet unknown binding partners of the invention has numerous advantages over the method known in the art. E.g. MMD-fusion proteins may be easily purified from Dictyostelium and the MMD fusion system may be transferred to a wide range of high eukaryotic cells. Furthermore, (i) the MMD-cDNA constructs may be directly used for expression in Dictyostelium and other eukaryotic cells; (ii) decreased background (since the system works with purified proteins and not with proteins within a cellular environment that, as in the case of the yeast 2-hybrid-system, leads to a high background of false positive clones); (iii) easy identification and isolation of the positive construct from mother plates; and (iv) the procedure may be highly automated, since all steps in the interaction screening may be performed in microtiter well plates.

30

#### Description of figures

In figure 1 the structure of M761-2R-R238E, an example for a recombinant protein of the invention, is shown. Although two molecules are present in the crystallographic

asymmetric unit, only one is shown here. The two molecules are essentially identical throughout the myosin motor domain (residues 2-761) exemplifying component (1) of the recombinant protein of the invention. However, upon  
5 leaving the converter domain, the lever arms assume slightly different orientations and deviate at the ends by 19.4 Å. In fig. 1(A) a complete molecule (recombinant protein of the invention) spanning amino acids 2-1010 is shown. No electron density was observed for five residues  
10 at the N-terminus, the loop region 205-208, and one residue at the C-terminus. The N-terminal domain (2-200) is shown in green, 50 kDa domain in red (201-613), C-terminal and converter domain in blue (614-761), linker region in orange (762-764) (component (3)) of the  
15 recombinant protein of the invention),  $\alpha$ -actinin lever arm in yellow (765-1003) (component (2) of the recombinant protein of the invention) and seven histidines from the His<sub>6</sub> purification tag in gray (1004-1010), which are linked as specified for an preferred embodiment of the  
20 present invention. The linker region (component (3)) is composed of three residues (Leu-Gly-Arg) introduced during cloning. The observed lever arm is ~140 Å long (measured from C $\alpha$  of 761 to C $\alpha$  of 1010). Each  $\alpha$ -actinin repeat contributes ~65 Å, and the histidine purification tag  
25 another 10 Å. Helices 1-3 make up the first  $\alpha$ -actinin repeat, and 4-6 the second. The arrowhead indicates the  $\alpha$ -helical region linking the two repeats. The disruptive kink in helix 2 is caused by the presence of two adjacent proline residues (see fig. 5A). In fig. 1(B) a detailed  
30 view of the linker region joining the myosin converter domain to helix 1 of  $\alpha$ -actinin is depicted. The view is rotated 180° around a vertical axis from that in fig. 1(A).



In figure 2 a detailed view of the conserved salt bridge linking switch I and switch II is shown as a result of purifying, crystallizing a recombinant protein of the invention and finally solving the structure of that protein according to methods of the invention. The conserved nucleotide binding/sensing elements found in all myosins, kinesins, and G-proteins are highlighted for the P-loop in blue, switch I in green, and switch II in red. Fig. 2(A) shows the structure of *Dictyostelium* myosin II motor complexed with Mg-ADP-BeF<sub>3</sub>. As in Mg-ADP-VO<sub>4</sub> (Smith and Rayment, 1996a) and Mg-ADP-BeF<sub>3</sub> (Dominguez et al., 1998) structures, switch I and switch II are closed. The conserved salt bridge between residues R238 and E459 is shown as a ball-and-stick model surrounded by 2.6 Å experimental 2f<sub>o</sub>-f<sub>c</sub> electron density (blue wire-frame), contoured at 1 σ. As expected for a salt bridge, the electron density is continuous between the residues, which point toward each other. In fig. 2(B) the same region as observed in the crystal structure of M761-2R-R238E is shown. The electron density was calculated from a model with alanins at positions 238 and 459 in order to eliminate model bias. Electron density for two glutamic acid residues is clearly visible, but the side chain of E238 now points away from E459 and the switch II loop has moved away from switch I. In fig. 2(C) the same region showing a superposition of the M761-2R-R238E structure with a structure of *Dictyostelium*, myosin II motor complexed with Mg-ADP-VO<sub>4</sub> (PDB code 1VOM) (Smith and Rayment, 1996a). The nucleotide and R238-E459 salt bridge are shown as ball-and-stick models. Both the P-loop and switch I regions are in essentially identical conformations in both structures. However, the switch II region (red) shifts to the right, toward the nucleotide, by ~5 Å in the Mg-ADP-VO<sub>4</sub> structure, allowing the formation of the R238-E459 salt bridge.

Figure 3 shows the orientation of the myosin lever arm, a segment of component (1) of an example for a recombinant protein of the invention. Shown in yellow are five molecules of actin making up part of a helical actin filament. Modeled on to this are myosin in the "pre-power-stroke" up/closed orientation in red, the "post-power-stroke" down/open orientation in blue, and the M761-2R-R238E structure in green. The up, down, and actomyosin complex structures were modeled. The M761-2R-R238E structure was then aligned to the core domain of the down/open structure via residues 160-200, which includes the highly conserved P-loop region. It is noted that in the M761-2R-R238E structure, the helix leaving the converter domain initially superposes with the down/open structure, but then deviates due to the different helical bend of the  $\alpha$ -actinin.

In figure 4 the structure of  $\alpha$ -actinin repeats 1 and 2 are shown.  $\alpha$ -Actinin is an example for component (2) of the recombinant protein of the invention, which means  $\alpha$ -actinin is the target protein in this example. Its structure was solved using purification and crystallization methods of the present invention. The structure of the fig. 4(A) depicts in yellow an  $\alpha$ -carbon chain trace of the 6 helices making up repeats 1 (helices labeled 1-3) and 2 (helices labeled 4-6). The 17 hydrophobic aromatic amino acid residues stabilizing the triple-helical packing are shown in green (7 tyrosines, 6 phenylalanines and 4 tryptophans). Shown in red are two adjacent proline residues, which cause a kink, but not a break in  $\alpha$ -helix 2 of repeat 1. The uninterrupted  $\alpha$ -helix linking repeats 1 and 2 is shown in orange. Fig. 4(B) exemplifies a detailed view of the linker region, highlighting the stabilizing hydrophobic and hydrogen bonding interactions. Colours and orientation are

identical to those in fig. 4(A). Side chains are shown as ball-and-stick models, with the exception of Asp796 and Ser797, in which only the  $\alpha$ -carbon atoms involved in hydrophobic contacts are shown for clarity. The salt bridge between Arg880 and Glu877, and the hydrogen bond between Arg880 and the carbonyl oxygen of Leu956 (also shown as a ball-and-stick model), are shown as dashed lines.

Figure 5 is a comparison of *Dictyostelium*  $\alpha$ -actinin with human  $\alpha$ -actinin and human  $\alpha$ -spectrin. Fig. 5(A) shows the overlapping repeat 2 region of *Dictyostelium* (yellow) and human (blue)  $\alpha$ -actinin are shown as ribbon diagrams. Helices are numbered as described above for *Dictyostelium*  $\alpha$ -actinin and, in parentheses, as described previously for human  $\alpha$ -actinin (Djinovic-Carugo et al., 1999). The largest differences occur in the loop region connecting helices 4 and 5, indicated by an arrow, where the human  $\alpha$ -actinin structure would seriously overlap with *Dictyostelium* helix 6. In fig. 5(B) the alignment of *Dictyostelium* repeat 2 (yellow) with repeat 16 human  $\alpha$ -spectrin (green) is shown as ribbon diagrams. Helices are numbered as described above for the *Dictyostelium* protein and, in parentheses, as described previously for the human protein (Grum et al., 1999). *Dictyostelium* helix 4 and  $\alpha$ -spectrin helix A, which are in the background, are colored white for clarity. In general, the two structures align more closely than the human/*Dictyostelium* alignment described above. The largest difference occurs in the loop region connecting helices 5 and 6, indicated by an arrow, where the human  $\alpha$ -spectrin structure is moved in respect to the *Dictyostelium*  $\alpha$ -actinin structure as a result of a proline-induced kink in helix B.

Fig. 6 shows the amino acid sequence (one-letter-code) for component (1) of recombinant protein M761-2R R238E exemplifying a recombinant protein of the invention.

In fig. 7 the whole sequence of recombinant protein M761-2R R238E is depicted comprising as component (1) the amino acid sequence of the myosin II motor domain of Dictyostelium, a three amino acid linker region ( ) as component (3) and the  $\alpha$ -actinin amino acid sequence being the target sequence in this example (one-letter-code). Fig. 8 is the DNA sequence coding for recombinant protein M761-2R R238E such that the sequence of fig. 8 corresponds to the sequence of fig. 7 on the genetic level.

### Examples of the present invention

#### Example 1

##### (a) Expression

The expression-vector pDXA-3H, that was used for the production of M761-2R R238E, carries the origin of replication of the *Dictyostelium* high copy number plasmid Ddp2 (Leiting et al. 1990, *Molecular And Cellular Biology* 10, 3727-3736; Chang et al. 1990, *Nucleic Acids Research* 17, 3655-3661), an expression cassette consisting of the strong, constitutive *actin15* promoter, a translational start codon upstream from a multiple cloning site (MCS), and sequences for the addition of a histidine octamer at the carboxy terminus of any protein. Plasmids derived from pDXA-3H were transformed into *orf*<sup>+</sup>-cells. These cells carry several integrated copies of the *rep* gene which is essential in trans for the replication of plasmids that carry the Ddp2 origin (Leiting et al. 1990, *Molecular And Cellular Biology* 10, 3727-3736; Slade et al. 1990, *Plasmid* 24, 195-207). The myosin- $\alpha$ -actinin fusion was created by linking codon 761 of the *Dictyostelium mhca* gene to codon 264 of the *Dictyostelium*  $\alpha$ -actinin gene.

The resulting construct pDH12-2R extended to codon 505 of the  $\alpha$ -actinin gene. Plasmid pDH20 was generated by insertion of the first 765 codons of Dictyostelium myosin II into the MCS of pDXA-3H (Furch et al. 1998, *Biochemistry*, 37, 6317-6326). Site directed mutagenesis was used to generate plasmid pDH20(R238E) encoding a motor domain fragment with the single point mutation R238E. Replacement of the 2 kb *SafI*-*BstXI* fragment of pDH12-2R with the corresponding fragment from pDH20(R238E) was used to generate the expression vector for the production of M761-2R R238E, the fusion protein and an example for a recombinant protein of the invention, containing thus both a point mutation in the active site and a C-terminal extension consisting of two  $\alpha$ -actinin repeats.

#### (b) Purification

The overexpressed protein was purified by  $\text{Ni}^{2+}$ -chelate affinity chromatography as described by Manstein and Hunt (J. Muscle Res. Cell Motil., 1995, 16, 325) und Manstein et al. (Gene 1995, 162, 129). Both afore-cited documents are incorporated into the disclosure of the present invention by their complete contents.

Cells expressing the histidine octamer tagged fusion protein were grown in 5 l flasks containing 2.5 l DD-Broth 20. DD-Broth 20 contains (per litre): 20 g protease peptone (Oxoid), 7 g yeast extract (Oxoid), 8 g glucose, 0.33 g  $\text{Na}_2\text{HPO}_4 \cdot 7\text{H}_2\text{O}$ , and 0.35g  $\text{KH}_2\text{PO}_4$ . The flasks were incubated on a gyratory shaker at 200 rpm and 21°C. Cells were harvested at a density of  $6 \times 10^6 \text{ ml}^{-1}$  by centrifugation for 7 min at 2,700 rpm in a Beckman J-6 centrifuge and washed once in phosphate buffered saline. The wet weight of the resulting cell pellet was determined. Typically, 35 g were obtained from a 15 l shaking culture. The cells were resuspended in 140 ml of

32

Lysis Buffer (50 mM Tris.HCl, pH 8.0, 2 mM EDTA, 0.2 mM EGTA, 1 mM dithiothreitol (DTT), 5 mM benzamidine, 40 mg/ml TLCK, 20 mg/ml N-tosyl-L-phenylalanine chloromethyl ketone (TPCK), 200 mM phenylmethylsulfonyl fluoride (PMSF), 0.04 %  $\text{NaN}_3$ ).

Cell lysis was induced by the addition of 70 ml of Lysis Buffer containing 1 % Triton-X100, 15 mg/ml RNaseA (Sigma) and 100 units of alkaline phosphatase. The lysate was incubated on ice for one hour. Upon centrifugation (230,000g, 1 hour), the recombinant protein remained in the pellet. The pellet was washed in 100 ml of HKM buffer (50 mM HEPES, pH 7.3, 30 mM KAc, 10 mM  $\text{MgSO}_4$ , 7 mM  $\beta$ -mercaptoethanol, 5 mM benzamidine, 40 mg/ml PMSF) and centrifuged for 45 min at 230,000g. The recombinant protein was released into the supernatant by extraction of the resulting pellet with 60 ml HKM buffer containing 10 mM ATP. After centrifugation (500,000g, 45 min.), the supernatant was loaded using a peristaltic pump onto a  $\text{Ni}^{2+}$ -nitrilotriacetic acid ( $\text{Ni}^{2+}$ -NTA) affinity column (1.5 x 10 cm) (Qiagen). The flow-rate was adjusted to approximately 3 ml  $\text{min}^{-1}$ . After loading was completed the column was connected to a Waters 650M chromatography system. The column was washed briefly in Low Salt buffer (50 mM HEPES, pH 7.3, 30 mM KAc, 3 mM benzamidine), High Salt buffer (as Low Salt Buffer, but with 300 mM KAc), and Low Salt Buffer containing 50 mM imidazole. the recombinant myosin was eluted using a linear gradient of Low Salt Buffer and Imidazole Buffer (0.5 M imidazole, pH 7.3, 3 mM benzamidine), starting with 10 % Imidazole Buffer and reaching 100 % after 15 minutes. The flow rate was 3 ml  $\text{min}^{-1}$  and 3 ml fractions were collected. Absorbance at 280 nm was monitored. SDS gels were run to check the purity of the eluted protein.

35

The pooled fractions were dialysed immediately against Storage Buffer (20 mM HEPES, 0.5 mM EDTA, 1 mM DTT, pH 7.0) containing 3% sucrose and the purified protein could be stored at -80°C for several months without apparent loss of enzymatic activity. Actin-activated ATPase activity was measured by the release of inorganic phosphate.

### (c) Crystallization

Crystals of the overexpressed and purified recombinant protein M761-2R R238E were grown by the hanging drop method at 7°C. The drops contained equal volumes (2.2  $\mu$ l) of the protein solution and the mother liquor. The mother liquor contained 12% PEGM 5K, 170 mM NaCl, 50 mM HEPES-NaOH pH 7.2, 5 mM MgCl<sub>2</sub>, 5 mM DTT, 0.5 mM EGTA and 2% 2-methyl-1,3-propanediol. The protein solution (5 mg/ml) contained additionally 200  $\mu$ M ADP and 200  $\mu$ M vanadate, and was incubated on ice for 1 h before setting up the drops. Crystals normally appeared after 7-8 days and reached maximum dimensions of 0.1 x 0.3 x 0.9 mm. Crystals were transferred to a solution of mother liquor plus 30% glycerol and frozen in liquid nitrogen for storage and data collection.

### (d) Crystallography and structure refinement

Diffraction data for the crystals of the recombinant protein M761-2R R238E were collected at ESRF beamline ID-13 on a MarCCD detector and integrated and scaled using the program XDS (Kabsch, 1993, J. Appl. Cryst., 26, 795), producing a data set 97.7% complete to 2.8 Å with 4-fold redundancy and an  $R_{\text{sym}}$  of 11.0%. The M761-2R-R238E crystals belonged to space group P2<sub>1</sub>2<sub>1</sub>2 with two molecules in the asymmetric unit. Molecular replacement was performed with the program AMoRe (Navaza, 1994, Acta Cryst. A 50, 157) using the crystal structure of Dictyostelium myosin residues 2-759 complexed with Mg-ADP-BeF<sub>x</sub> (PDB code 1mmd) (Fisher et al., 1995, Biochemistry, 34, 8960) as a starting model (the nucleotide and the

side chains beyond C $\beta$  of residues 238 and 459 were excluded).

Initial maps showed clear helical density for the first repeat of the  $\alpha$ -actinin lever arm, which was built as a poly-alanine model using the program O (7.0 for WindowsNT). Following several rounds of simulated annealing refinement using torsional dynamics and a maximum likelihood target with the program CNS v0.9a (Brünger et al., 1998, Acta Cryst. D, 54, 905), the second  $\alpha$ -actinin repeat was visible and built. Subsequent rounds of model building and refinement (including bulk solvent correction) produced the final structure of two M761-2R-R238E molecules containing 1005 residues each, two molecules of Mg-ADP and 14 water molecules (R-factor, 24.1%; R<sub>free</sub>, 29.9%). Ramachandran analysis shows all non-glycine residues to be in allowed regions. Figures were made using the programs Bobscript (Esnouf, 1997, J. Mol. Graph. Model., 15, 132) and Raster3D (Merritt and Bacon, 1997, Methods Enzymol., 277, 505).

## Example 2

Myosin-Fusion-System for isolating interacting proteins/protein binding partners

### (a) Preparation

In order to demonstrate the function of the myosin-fusion-system a library of cDNA was fused to the C-terminus of a myosin motor domain (MMD) and expressed in *Dictyostelium* or another eukaryotic system. Clonal transformants were probed with the bait-protein of choice fused to  $\beta$ -galactosidase. The myosin motor domain was His- or epitope-tagged at the N-terminus.

Experimentally, cells were transformed with the MMD-cDNA library and clones were grown and kept in 96 wells plates. The bait- $\beta$ -gal fusion protein was transformed in



*Dictyostelium* Orf+ cells and grown in an appropriate quantity (1 clonal cell line). Upon reaching confluence, the MMD-cDNA clones in the 96 wells plates were washed once in the plates with PBS and then lysed by adding  
5 lysis buffer containing Triton X-100 (or, alternatively, NP-40), at the same time the ATP pool was depleted by the addition of alkaline phosphatase. The actin-based cytoskeleton with all myosin and also the M765-fusion-proteins were pelleted by centrifugation and washed with  
10 lysis buffer. The myosin was released from the pellets by the addition of  $Mg^{2+}$ -ATP. The ATP-insoluble fraction was pelleted and the supernatant transferred to 96 wells plates coated with Ni-NTA. The His-tagged products of the MMD-cDNA were shown to bind to these plates. After  
15 extensive washing the coated plates were incubated with the bait- $\beta$ -gal construct. Again, after extensive washing the plates were incubated with a substrate for  $\beta$ -gal, in this case CPRG (red color OD<sub>574</sub>) or ONPG (yellow OD<sub>415</sub>), and the  $\beta$ -gal activity was determined with a microtiter plate  
20 reader. High  $\beta$ -gal activity indicated a strong interaction between the bait and the product of the target cDNA.

The selected clones were then recovered from the original  
25 96 wells plates. The MMD-cDNA-clone was expressed in and purified from *Dictyostelium* by standard myosin motor domain purification. For further biochemical and structural characterization, the isolated gene product was either cleaved with an appropriate protease to  
30 release it from the MMD or was used directly in the fusion form for kinetics or crystallization experiments.

#### (b) Interaction Test

The method of the invention was tested by expressing MMD-  
35 Rac1A and DRG-2D- $\beta$ -gal (the DRG-2D construct acts as an exchange factor for the small G-protein Rac1A).

The MMD-Rac1A cells were cloned, grown in 96 wells plates, washed, lysed and ATP extracted as described above. The Ni-NTA coated plates were then incubated with the ATP-released protein fraction. The cells expressing the DRG-2D- $\beta$ -gal were grown in shaking suspension and washed and lysed under the same conditions. The DRG-2D- $\beta$ -gal supernatant was incubated at different dilutions. As controls wells were incubated without bait (DRG-2D- $\beta$ -gal) or without MMD-Rac1A or with MMD alone. All controls were negative after staining for  $\beta$ -gal, whereas the incubations with immobilized MMD-Rac1A and the bait gave a signal, which was dependent on the concentration of added bait.

15

In conclusion, the interaction between DRG-2D and Rac1A was shown by the method of the invention, whereas it could not be shown when using the yeast two-hybrid system. Therefore, the method of the invention has definitely advantages over the yeast-two-hybrid system or other techniques developed to identify protein-protein interactions and known in the art.

25

**SAMSON & PARTNER**

PATENTANWÄLTE · EUROPEAN PATENT ATTORNEYS · EUROPEAN TRADE MARK ATTORNEYS

UNSER ZEICHEN/OUR REF

DATUM/DATE

EPO - Munich  
24

12 Jan. 2001

## Claims

1. Recombinant protein characterized in that it contains as component (1) an amino acid sequence of a member of the myosin or kinesin protein superfamilies or an amino acid sequence of an analog, fragment or derivative of a member of the myosin or kinesin protein superfamilies, as component (2) any amino acid sequence of at least 20 amino acids in length, and as component (3) a linker region of at least 2 amino acids between components (1) and (2).  
5
2. Recombinant protein according to claim 1 characterized in that it contains as component (1) an amino acid sequence of a member of the myosin I, II, III, IV, V, VIII, VI, X, or XI or a member of kinesin I or II families or an amino acid sequence of an analog, fragment or derivative of a member of the aforementioned myosin and kinesin families.  
15
3. Recombinant protein according to claim 1 or 2 characterized in that it contains as component (1) an amino acid sequence for the motor domain of a kinesin or myosin family member or an analog, fragment or derivative thereof.  
20
4. Recombinant protein according to any of the preceding claims characterized in that it contains as component (3) a stretch of 3 amino acids with a Gly in the middle.  
25
5. Recombinant protein according to any of the preceding claims characterized in that it contains

as component (2) the sequence of an esterase, hydrolase, phosphatase, kinase, protease, channel, structural protein (e.g. coronin, spectrin), receptor, particularly a neuronal or immunologically relevant receptor (e.g. superfamily of TNF receptors), transcription factor, DNA/RNA-binding protein, lipoprotein or glycoprotein or an analog, derivative or fragment thereof.

6. Recombinant protein according to any of the preceding claims 1 to 5 characterized in that it contains as component (1) an amino acid sequence as shown in figure 6 and as component (3) the linker amino acid sequence Leu-Gly-Arg.
7. Recombinant protein according to any of preceding claims 1 to 6 characterized in that it contains a tag sequence, particularly at the N- or C-terminus of the recombinant protein.
8. DNA sequence characterized in that it contains a sequence which codes for an amino acid sequence according to any of the preceding claims 1 to 7.
9. Vector containing a DNA sequence according to claim 8.
10. Vector according to claim 9 capable of being expressed in a eukaryotic host cell.
11. Vector according to claim 9 or 10 capable of being expressed in cells of the species Dictyostelium.
12. Transformed eukaryotic host cell containing a vector according to any of preceding claims 9 to 11.

13. Transformed eukaryotic host cell according to claim 12 characterized in that it is a cell from the species Dictyostelium.
14. Method for producing a recombinant protein according to any of the preceding claims 1 to 7 characterized in that it comprises (a) preparing a vector according to any of preceding claims 9 to 11, (b) transforming eukaryotic host cells with a vector obtainable from step (a), (c) growing transformed host cells according to claim 12 or 13 and obtainable from step (b) under conditions suitable for the expression of said recombinant protein.
15. Method for purifying a recombinant protein according to any of preceding claims 1 to 7 characterized in that it comprises (a) preparing a vector according to any of preceding claims 9 to 11, (b) transforming eukaryotic host cells with a vector obtainable from step (a), (c) growing transformed host cells according to claim 12 or 13 and obtainable from step (b) under conditions suitable for the overexpression of said recombinant protein, (d) purifying overexpressed recombinant protein by binding to endogenous actin/microtubules (mt) of the eukaryotic host cell, and (e) specifically releasing bound recombinant protein from actin/mt.
16. Method according to claim 15 characterized in that step (e) comprises releasing the recombinant protein by adding a natural substrate of component (1) of the recombinant protein.
17. Method according to claim 16 characterized in that the natural substrate is ATP.
18. Method according to any of preceding claims 15 to 17 characterized in that it comprises as further step


40

(f) at least one additional purification step by biochemical, particularly chromatographic, and/or physical methods.

- 5 19. Method according to claim 18 characterized in that step (f) comprises purifying by affinity chromatography, particularly using metals or antibodies as ligands.
20. Recombinant protein obtainable from a method according to any of preceding claims 15 to 19.
- 10 21. Method for crystallizing a recombinant protein according to any of preceding claims 1 to 7 characterized in that it comprises (a) a purification step according to a method according to any of preceding claims 15 to 19 and (b)
- 15 crystallizing the purified recombinant protein obtained in step (a).
22. Protein crystal characterized in that the crystal is built by a network of recombinant proteins according to any of preceding claims 1 to 7 that form the
- 20 crystal lattice.
23. Method for elucidating the atomic structure of a protein crystal according to claim 22 characterized in that it comprises (a) a crystallization step according to claim 21, (b) collecting X-ray
- 25 diffraction data for a crystal obtained in step (a), and (c) calculating the atomic structure of a recombinant protein by transformation of the data obtained in step (b).
- 30

EPO - Munich  
24

12 Jan. 2001

Fig. 1, Kliche *et al.*

2/9




Fig. 2, Kliche *et al.*






Fig. 3, Kliche *et al.*





Fig. 4, Kliche *et al.*

Fig. 5. Kliche *et al.*

6/9

Fig. 6

MDGTEDPIHDRTSDYHKYLKVKQGDSDFKLTVSDKRYIWYNPDPKERDSYECGEIVSE  
TSDSFTFKTVDGQDRQVKDDANQRNPIKFDGVEDMSELSYLNPAVFHNLVRYNQDL  
IYTYSGLFLVAVNPFKRIPIYTQEMVDIFKGRRRNEVAPHIFAISDVAYRSMDDRQNO  
SLITGESGAGKTENTKKVIQYLASVAGRNOANGSGVLEQQILQANPILEAFGNAKTTR  
NNNSSRFGKFIEIQFNSAGFISGASIQSYLLEKSRVVFQSETERNYHIFYQLLAGATAE  
EKKALHLAGPESFNYLNQSGCVDIKGVSDSEEFKITRQAMDIVGFSQEEQMSIFKIIAG  
ILHLGNIKFEKGAGEGAVLKDKTALNAASTVFGVNPSVLEKALMEPRILAGRDLVAQHL  
NVEKSSSSRDALVKALYGRFLWLVKKINNVLQERKAYFIGVLDISGFEIFKVNSFEQ  
LCINYTNEKLQQFFNHHMFKLEQEYLKEKINWTFIDFGLDSQATIDLIDGRQPPGILA  
LLDEQSVFPNATDNTLITKLHSHFSKKNAYEPRFSKTEFGVTHYAGQVMYEIQDWLE  
KNKDPLQQDLELCFKDSSDNVTKLFNDPNIASRAKKGANFITVAAQYKEQLASLMATL  
ETTNPHFVRCIIPNNKQLPAKLEDKVVLQDLRCNGVLEGIRITRKGFPNRIIYADFVKR  
YYLLAPNVPRDAEDSQATDAVLKHLNIDPEQYRFGITKIFFRAGQLARIEEAREQR

7/9

Fig 7

MDGTEDPIHDRTSDYHKYLKVKQGSDLFKLTVSDKRYIWYNPDPKERDSYECGEIVSE  
TSDSFTFKTVDGQDRQVKKDDANQRNPIKFDGVEDMSELSYLNPAVFHNLVRVYNQDL  
IYTYSGFLVAVNPFKRIPIYTQEMVDIFKGRRRNEVAPHIFAISDVAYRSMLDDRQNO  
SLLITGESGAGKTENTKKVIQYLASVAGRNOANGSGVLEQQILQANPILEAFGNAKTTR  
NNSSRFKGFIEIQFNSAGFISGASIQSYLLEKSRVVFQSETERNYHIFYQLLAGATAE  
EKKALHLAGPESFNYLNQSGCVDIKGVSDSEEFKITRQAMDIVGFSQEEQMSIFKIIAG  
ILHLGNIKFEGGAGEGAVLKDKTALNAASTVFGVNPSVLEKALMEPRILAGRDLVAQHL  
NVEKSSSSRDALVKALYGRFLWLKKNVLCQERKAYFIGVLDISGFEIFKVNSFEQ  
LCINYTNEKLQQFFNHMHFKLEQEEYLKEKINWTFIDFGLDSQATIDLIDGRQPPGILA  
LLDEQSVFPNATDNTLITKLHSHFSKKNAYEPRFSKTEFGVTHYAGQVMYEIQDWLE  
KNKDPLQQDLELCFKDSSDNVVTCLFNDPNIASRAKKGANFITVAAQYKEQLASLMATL  
ETTNPHFVRCIIPNNKQLPAKLEDKVVLDDQLRCNGVLEGIRITRKGFPNRIIYADFVKR  
YYLLAPNVPRDAEDSQKATDAVLKHLNIDPEQYRFGITKIFFRAGQLARIEEAREQRLG  
SEQTKSDYLKRANELVQWINDKQASLESRDFGDSIESVQSFMNAHKEYKKTEKPPKGQE  
VSELEAIYNSLQTKLRLIKREPFVAPAGLTPNEIDSTWSALEKAEQEHAELRIELKRQ  
KKIAVLLQKYNRIILKKLENWATTKSVYLGNETGDSITAVQAKLKNLEAFDGECSLEG  
QNSDLLSILAQLTELNYNGVPELTERKDTFFAQQWTGVKSSAETYKNTLLAELERLQK  
IEDALHHHHHHH

8/9

Fig 8

ATGGATGGTACCGAGGATCCAATTCATGATAGAACTTCAGATTATCACAAATACTTAAA  
AGTTAAACAAGGTGATTCTGATTTATTTAACTTACTGTTTCAGATAAGAGATACATTT  
GGTATAATCCAGATCCAAAAGAAAGAGATTCATATGAATGTGGTGAAATTGTTTCAGAA  
ACCTCTGATTCTTTCACATTCAAACCGTTGATGGTCAAGACAGACAAGTCAAAAAGGA  
TGATGCCAATCAACGTAATCCAATCAAATTCGATGGTGTGCAAGATATGTCTGAATTAT  
CATACCTCAATGAACCAGCAGTTTTCCACAATCTCCGTGTTTCGTTACAATCAAGATTTA  
ATTTACACCTATTCAGGTCTCTTTTTGGTTGCCGTCAATCCATTCAAGAGAATTCCAAT  
CTACACTCAAGAGATGGTTGATATCTTCAAAGGTGCTAGAAGAAATGAAGTTGCCCCAC  
ATATTTTCGCCATTTCTGATGTTGCCTATCGTTCAATGTTAGATGATCGTCAAAATCAA  
TCACTCTTAATCACTGGTGAATCTGGTGCTGGTAAGACTGAAAACACCAAAAAGGTCAT  
TCAATATCTTGCATCTGTGCTGGTCTGTAATCAAGCCAATGGTAGTGGTGTATTGGAAC  
AACAAATTCTCCAAGCCAATCCAATCCTTGAAGCTTTTGGTAATGCCAAAACCAACCGT  
AACACAATTCTCTCGTTTCGGTAAATTCATTGAAATTCAATTCAACAGTGCTGGTTT  
CATTAGTGGTGCTTCAATTCAATCCTACCTTTTAGAGAAATCACGTGTCTGTTTCCAAT  
CTGAAACCGAACGTAATTATCACATTTTCTATCAACTCTTAGCTGGTGCCACCGCCGAA  
GAAAAGAAAGCTCTTCACTTGGCTGGTCCAGAATCATTCAACTACTTAAATCAAAGTGG  
TTGTGTTGATATCAAAGGTGTCTCTGATAGTGAAGAATTCAAATCACTCGTCAAGCTA  
TGGACATTGTTGGTTTCTCACAAGAAGAACAATGTCAATCTTTAAGATCATTGCTGGT  
ATCTTACATTTAGGTAACATCAAATTCGAAAAGGTGCTGGTGAAGGTGCTGTCTCTCAA  
AGACAAAACCGCCCTCAACGCTGCTTCAACCGTCTTTGGTGTCAATCCATCAGTCCTTG  
AAAAGGCTCTCATGGAACCACGTATTTTAGCCGGTCTGTGATTTAGTTGCTCAACATCTC  
AACGTTGAAAATCCTCATCATCAAGAGACGCTCTTGTCAAAGCTCTCTATGGTCGTCT  
TTTCCTCTGGTTGGTCAAAAAGATCAACAATGTCCTCTGTCAAGAGAGAAAAGCTTACT  
TTATTGGTGTTTTGGATATTTCAAGTTTTGAAATTTCAAAGTCAATTCATTGGAACAA  
TTATGTATCAATTATACCAATGAAAACTCCAACAATTCTTCAATCACCATATGTTCAA  
ATTGGAACAAGAAGAATATCTTAAAGAGAAAATCAATTGGACTTTCATCGATTTTGGTC  
TTGATTCACAAGCCACTATCGATTTAATTGATGGTCGTCAACCACCAGGTATTTTAGCT  
CTTTTGGATGAACAATCTGTTTTCCCAAATGCCACCGATAATACTTTAATCACCAAAT  
CCACAGTCACTTTAGCAAGAAGACGCCAAATACGAAGAACCAGTTTCTCCAAAACCG  
AATTTGGTGTTACCCATTATGCTGGTCAAGTCATGTATGAGATTCAAGATTGGTTAGAA  
AAGAACAAGATCCATTACAACAAGATCTCGAACTTTGCTTCAAAGATTCAACAGACAA  
CGTTGTCACCAAACCTTTTCAATGATCCAAACATTGCCAGTCGTGCAAAGAAAGGTGCAA  
ACTTTATCACTGTCGCCGCTCAATACAAGGAACAATTAGCCTCACTCATGGCNACCCTT  
GAAACCACCAACCCACATTTGTTTCGTTGTATCATTCCAAACAACAACAATTACCAGC  
CAAACCTCGAAGATAAAGTTGTCCTCGACCAATTACGTTGCAATGGTGTCTCTCGAAGGTA  
TTCGTATTACTCGTAAAGGTTTCCCAAATCGTATTATCTATGCCGATTTTCGTCAAACGT

9/9

TACTATTTATTAGCTCCAAACGTTCCAAGAGACGCTGAAGACTCACAAAAAGCCACCGA  
TGCTGTTCTCAAACATCTTAACATTGATCCAGAACAATATCGTTTCGGTATCACCAAGA  
TTTTCTTCCGTGCCGGTCAATTAGCTCGTATTGAAGAAGCTCGTGAACAACGTCTAGGA  
TCCGAACAAACCAAATCTGATTATCTTAAAAGAGCCAATGAACTCGTTCAATGGATTAA  
CGATAAACAAGCATCACTTGAATCACGTGATTTTGGTGATTCCATCGAATCTGTTCAA  
GTTTCATGAACGCTCATAAAGAATATAAAAAAACCAGAAAAACCACCAAAGGGTCAAGAA  
GTCTCTGAATTGGAAGCTATCTACAATTCATTACAACTAAATTACGTTTAATTAAACG  
TGAACCATTTGTTGCACCAGCTGGTCTCACTCCAAATGAAATCGATTCCACTTGGTCCG  
CTTTAGAGAAAGCTGAACAAGAACATGCTGAAGCCCTCCGTATTGAACTCAAACGTCAA  
AAGAAAATTGCAGTTCTCTTACAAAAATACAATCGTATTCTCAAGAACTCGAAAACGTG  
GGCCACCACCAAATCTGTCTACCTCGGTTCCAATGAAACCGGTGACAGTATCACTGCTG  
TTCAAGCTAAATTAAAGAATTTAGAAGCTTTTGATGGTGAATGTCAATCATTGGAAGGT  
CAATCAAACCTCTGATCTCCTCAGCATTCTTGCTCAATTAACCTGAACTCAACTACAATGG  
TGTACCAGAACTCACTGAACGTAAAGATACATTCTTTGCTCAACAATGGACTGGTGTTA  
AATCATCTGCTGAAACCTACAAAAACACTCTTTTAGCTGAACTTGAAAGACTCCAAAAG  
ATTGAAGATGCATTACATCATCATCATCATCACCAC

Fig 8 Fortsetzung

